Roche Holding AG (XSWX:RO) 6-Month Price Index: 0.95 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:RO Roche Holding AG XSWX:RO
76 GF Score
Price CHF339.60
GF Value CHF268.89
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG 6-Month Price Index?

Roche Holding AG XSWX:RO +0.83% 76 6-Month Price Index is 0.95 as of Jul. 18, 2026. GuruFocus rates XSWX:RO with a GF Score™ of 76/100 and a GF Value™ of CHF268.89 (Modestly Overvalued). The stock has 7 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-07-18), Roche Holding AG's 6-Month Price Index is 0.95.

Roche Holding AG  (XSWX:RO) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Roche Holding AG 6-Month Price Index Related Terms

XSWX:RO vs LLY, JNJ, ABBV: 6-Month Price Index Comparison

For the Drug Manufacturers - General subindustry, Roche Holding AG's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XSWX:RO
76GF Score
Roche Holding AG XSWX:RO
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roche Holding AG  (XSWX:RO) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 0.95 mean?
Roche Holding AG (XSWX:RO) has a 6-Month Price Index of 0.95 as of Jul. 18, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Roche Holding AG and its competitors.
Is Roche Holding AG's 6-Month Price Index too high?
Roche Holding AG's current 6-Month Price Index is 0.95. Overall, Roche Holding AG has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's 6-Month Price Index compare to LLY and JNJ?
Roche Holding AG's 6-Month Price Index of 0.95 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Drug Manufacturers company?
A good 6-Month Price Index depends on the Drug Manufacturers industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Roche Holding AG and its competitors. Roche Holding AG's current 6-Month Price Index is 0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF268.89, compared to a current price of CHF339.60 — trading 26.3% above its estimated fair value. The current 6-Month Price Index is 0.95. Roche Holding AG's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current 6-Month Price Index is 0.95 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roche Holding AG (XSWX:RO) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of CHF339.60 is trading 26.3% above its estimated GF Value™ of CHF268.89. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for XSWX:RO:

  • 6-Month Price Index: 0.95
  • GF Value™: CHF268.89 vs. price of CHF339.60 (26.3% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
76GF Score

Get the complete analysis for XSWX:RO

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF339.60
Price
CHF268.89
GF Value